Enovis (NYSE:ENOV) Releases FY 2025 Earnings Guidance

Enovis (NYSE:ENOV) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 3.250-3.350 for the period, compared to the consensus earnings per share estimate of 3.180. The company issued revenue guidance of $2.2 billion-$2.3 billion, compared to the consensus revenue estimate of $2.3 billion.

Analysts Set New Price Targets

ENOV has been the subject of a number of research analyst reports. Canaccord Genuity Group cut their price objective on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. UBS Group restated a “buy” rating and set a $50.00 target price on shares of Enovis in a research report on Monday, January 5th. Evercore ISI reaffirmed an “outperform” rating on shares of Enovis in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a report on Wednesday, October 8th. Finally, BTIG Research assumed coverage on shares of Enovis in a report on Tuesday, January 6th. They set a “buy” rating and a $41.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Enovis Trading Down 9.2%

ENOV stock opened at $26.95 on Tuesday. The firm has a fifty day moving average price of $28.27 and a 200 day moving average price of $29.84. Enovis has a fifty-two week low of $25.47 and a fifty-two week high of $49.38. The firm has a market cap of $1.54 billion, a PE ratio of -1.14 and a beta of 1.52. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. The company had revenue of $383.81 million for the quarter. Enovis has set its FY 2025 guidance at 3.100-3.250 EPS. Sell-side analysts anticipate that Enovis will post 2.79 earnings per share for the current fiscal year.

Insider Transactions at Enovis

In related news, EVP Daniel A. Pryor sold 999 shares of Enovis stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John Kleckner acquired 2,468 shares of Enovis stock in a transaction on Tuesday, November 25th. The shares were bought at an average cost of $30.32 per share, for a total transaction of $74,829.76. Following the completion of the purchase, the insider directly owned 12,302 shares of the company’s stock, valued at $372,996.64. The trade was a 25.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 2.70% of the stock is currently owned by company insiders.

Institutional Trading of Enovis

Institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC boosted its stake in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. Danske Bank A S purchased a new position in Enovis in the 3rd quarter worth about $64,000. iSAM Funds UK Ltd bought a new stake in Enovis during the 3rd quarter valued at about $80,000. Brown Brothers Harriman & Co. bought a new stake in Enovis during the 3rd quarter valued at about $90,000. Finally, Tower Research Capital LLC TRC boosted its position in Enovis by 578.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,347 shares of the company’s stock valued at $136,000 after buying an additional 3,706 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.